ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1560

What Will Determine Adherence to Pharmaceutical Treatment for Rheumatoid Arthritis? A Systematic Review

Annelieke Pasma1, Adriaan van 't Spijker2, Jan van Busschbach3, Johanna M.W. Hazes4 and Jolanda J. Luime5, 1Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, 2Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, 3Medical Psychology and Psychotherapy, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands, 5Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, DMARDs, nonsteroidal antiinflammatory drugs (NSAIDs) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Clinical Practice/Patient Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose:

In the early stages of Rheumatoid Arthritis (RA), adherence to the prescribed treatment is important to prevent irreversible joint damage. However, medication adherence rates in RA patients can be improved. To explain the suboptimal adherence, factors that influence adherence should be elucidated. These factors were last reviewed in 1982. Since then, treatment strategies for RA have changed, which means that nowadays different factors might play a role. Our aim is therefore to review adherence rates reported in the literature, to identify factors associated with adherence, to review the strength of the association between these factors and adherence and to cluster the identified factors according to the Health Belief Model (HBM) (figure 1.). 

Methods:

PubMed, PsycINFO, EMbase and CINAHL databases were systematically searched from inception to February 2011. Articles were included if they addressed medication adherence, used a reproducible definition, determinants and its statistical relationship. Methodological quality was assessed using a quality assessment list for observational studies derived from recommendations from Sanderson, Tatt and Higgins (2007). The strength of evidence for factors associated with adherence was assessed by defining 5 levels of evidence. Resulting factors were interpreted using the HBM.

Results:

18 out of the 1479 identified studies remained. Adherence rates ranged between 49.5% and 98.5%. 64 factors were identified and grouped according the HBM into demographic and psychosocial characteristics, cues to action and perceived benefits versus perceived barriers. The belief that the medication is necessary and DMARD use prior to the use of anti-TNF had strong evidence for a positive association with adherence. There is limited evidence for positive associations between adherence and race other than White, general cognition, satisfactory contact with the healthcare provider and the provision of adequate information from the healthcare provider. There is limited evidence for negative associations between adherence and having HMO insurance, weekly costs of TNF-I, having a busy lifestyle, receiving contradictory information or delivered information in an insensitive way by the rheumatologist. 18 factors were unrelated to adherence. The results are presented in figure 1.  

Conclusion:

The strongest relation with adherence is found for prior use of DMARDs before using anti-TNF and beliefs about medication. Because the last one is modifiable, this provides hope to improve medication adherence. Since research on factors influencing adherence has mostly focussed on demographic and disease futures, future studies should use a theoretical framework to explore the role of interpersonal and other relevant factors.



Disclosure:

A. Pasma,
None;

A. van ‘t Spijker,
None;

J. van Busschbach,
None;

J. M. W. Hazes,
None;

J. J. Luime,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-will-determine-adherence-to-pharmaceutical-treatment-for-rheumatoid-arthritis-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology